Redeye: Vitrolife - Updating our view on the case
Redeye updates on Vitrolife after a site visit and a change of lead analyst. The company continues exhibiting key hallmarks of quality, yet its shares are trading near a five-year low. While strategic initiatives are in place to address the muted growth trajectory observed over the past few years, we argue sustained acceleration will be required for the stock to regain momentum. We believe the market is likely to wait for tangible evidence of improved growth trajectory before re-rating the shares.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/